Niagen Bioscience Inc (NAGE) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
NAGE Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Niagen Bioscience Inc (NAGE) trades at a price-to-earnings ratio of 20.9x, with a stock price of $4.19 and trailing twelve-month earnings per share of $0.21.
The current P/E is 70% below its 5-year average of 70.0x. Over the past five years, NAGE's P/E has ranged from a low of 31.1x to a high of 193.1x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, NAGE is roughly in line with its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, NAGE trades roughly in line with the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NAGE DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NAGE P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 25.5 | 1.11 | -25% | |
| $15B | 32.0 | 13.69 | +42% | |
| $178B | 23.1 | 7.86 | +88%Best | |
| $151B | 19.5 | - | -4% | |
| $277B | 15.4Lowest | 0.73Best | +8% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
NAGE Historical P/E Data (2024–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $6.36 | $0.20 | 31.1x | -56% |
| FY2025 Q3 | $9.33 | $0.24 | 38.3x | -45% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $14.41 | $0.21 | 67.1x | -4% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $6.90 | $0.17 | 40.0x | -43% |
| FY2024 Q4 | $5.31 | $0.11 | 50.4x | -28% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $3.65 | $0.02 | 193.1x | +176% |
Average P/E for displayed period: 70.0x
See NAGE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NAGE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NAGE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNAGE — Frequently Asked Questions
Quick answers to the most common questions about buying NAGE stock.
Is NAGE stock overvalued or undervalued?
NAGE trades at 20.9x P/E, below its 5-year average of 70.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does NAGE's valuation compare to peers?
Niagen Bioscience Inc P/E of 20.9x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is NAGE's PEG ratio?
NAGE PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.